Biotechnology Research Misconduct Regulation In Russia.

1. Introduction

Biotechnology research misconduct in Russia refers to unlawful, unethical, or scientifically improper conduct during biological, medical, genetic, pharmaceutical, genomic, and other biotechnology-related research.

Research misconduct may involve:

Fabrication of experimental results or scientific data.

Falsification or manipulation of laboratory findings.

Plagiarism and unauthorized use of scientific publications.

Manipulation of clinical-trial results.

Misuse of human biological samples and genetic information.

Unauthorized genetic experimentation.

Concealment of adverse events in biotechnology research.

Breaches of research ethics and informed consent.

Misappropriation of research funding.

Deliberate concealment of scientific errors or safety risks.

An important legal distinction: Russia does not rely on one comprehensive statute exclusively governing all forms of scientific research misconduct. Instead, responsibility is distributed across legislation governing scientific activity, healthcare, clinical trials, personal data, intellectual property, employment, public funding, and criminal liability.

The applicable legal framework depends on the nature of the misconduct, the research institution, the funding arrangement, and the harm caused.

2. Major Russian legislation governing research misconduct

A. Federal Law No. 127-FZ of 23 August 1996 – On Science and State Scientific and Technical Policy

This is the principal general legislation governing scientific activity in Russia.

It establishes the legal framework for:

Scientific and technological research.

Rights and responsibilities of scientific researchers.

Scientific institutions and research organisations.

Government support for scientific development.

Protection of scientific results.

Responsible conduct of scientific and technical activities.

Article 4 is particularly relevant because it addresses the rights and obligations of scientific workers.

Researchers must conduct scientific and experimental activities without violating human rights and freedoms, harming human life or health, or damaging the environment.

Article 10 also allows the Government to regulate research and the use of scientific results where they may threaten national security, public health or the environment.

Application to biotechnology misconduct:

A biotechnology researcher who deliberately manipulates genetic experiments, conceals dangerous laboratory findings, or conducts research in a manner that harms human health may face institutional and other legal consequences.

ГАРАНТ+2

B. Federal Law No. 61-FZ of 12 April 2010 – On Circulation of Medicines

This legislation is especially important for pharmaceutical biotechnology, vaccine development, biological medicines and clinical research.

Article 38 regulates clinical trials of medicinal products.

Article 38(12) expressly provides that failure to comply with Good Clinical Practice (GCP) and falsification of clinical-trial results entail liability under Russian law.

The legislation also provides regulatory mechanisms for dealing with serious GCP violations, including suspension and termination of clinical trials.

Examples of prohibited or actionable misconduct include:

Fabricating clinical-trial participant records.

Manipulating vaccine efficacy results.

Concealing serious adverse reactions.

Falsifying laboratory reports.

Reporting clinical trials that were not actually conducted.

Failing to comply with approved research protocols.

Legal significance: This is one of the clearest statutory foundations for addressing research misconduct in biotechnology-related clinical trials.

WIPO+2

C. Federal Law No. 323-FZ of 21 November 2011 – On the Fundamentals of Health Protection of Citizens

This law protects patients participating in biomedical research.

Its relevance includes:

Patient rights and dignity.

Medical confidentiality.

Informed consent.

Protection against improper medical intervention.

Medical professional responsibilities.

Patient safety.

Biotechnology researchers working with human participants must respect applicable requirements governing medical intervention and informed consent.

For example, conducting experimental gene-related treatment without legally required consent may create civil, disciplinary, administrative or criminal consequences, depending on the circumstances.

D. Federal Law No. 152-FZ of 27 July 2006 – On Personal Data

This law is particularly important for genomic and genetic research.

Genetic research may involve:

DNA sequencing.

Genetic disease databases.

Human biological samples.

Hereditary disease information.

Genomic identification.

Biobank records.

Researchers must comply with applicable rules concerning lawful processing, confidentiality, data minimisation, security and consent.

Unauthorized disclosure or misuse of genetic and medical information can create additional liability.

static-0.minzdrav.gov.ru+1

E. Federal Law No. 180-FZ of 23 June 2016 – On Biomedical Cellular Products

This law regulates the development, preclinical research, clinical trials, examination, registration, production, quality control, storage and transportation of biomedical cellular products.

It is particularly relevant to:

Stem-cell research.

Cellular therapies.

Regenerative medicine.

Human-cell-based treatments.

Biomedical cellular product manufacturing.

Its regulatory framework is important when misconduct compromises product quality, safety, manufacturing records or clinical evidence.

However, its statutory scope must be distinguished from research involving human cells and tissues exclusively for scientific or educational purposes, which is treated differently under the legislation.

CIS Legislation

3. Main forms of biotechnology research misconduct in Russia

3.1 Fabrication of scientific data

Fabrication occurs when researchers invent experimental findings or create false scientific records.

Examples include:

Inventing DNA sequencing results.

Creating false gene-expression measurements.

Reporting nonexistent laboratory experiments.

Inventing clinical-trial participants.

Fabricating vaccine efficacy data.

Fabrication can invalidate scientific publications, undermine regulatory approvals and expose researchers to institutional and legal proceedings.

3.2 Falsification of research results

Falsification involves manipulating genuine research materials, processes or results so that the scientific record becomes misleading.

Examples include:

Altering genetic sequencing results.

Manipulating biological assay measurements.

Removing unfavourable experimental observations without scientific justification.

Changing clinical-trial records.

Concealing toxicological findings.

In clinical trials, Article 38(12) of Federal Law No. 61-FZ is particularly significant.

3.3 Scientific plagiarism

Plagiarism involves using another researcher's scientific work, data, ideas or publications without appropriate attribution.

In biotechnology, this may include:

Copying genetic research findings.

Misappropriating vaccine-development studies.

Reproducing laboratory research without attribution.

Claiming another scientist's experimental discoveries as one's own.

Improperly claiming authorship of scientific publications.

Possible consequences include withdrawal of academic degrees, employment sanctions and copyright proceedings.

3.4 Clinical-trial misconduct

Clinical-trial misconduct is particularly serious because it can directly affect patient safety.

Examples include:

Conducting trials without required authorisation.

Falsifying patient consent documents.

Concealing adverse events.

Manipulating randomisation.

Misreporting treatment outcomes.

Deviating from approved research protocols without proper justification.

Regulatory authorities may suspend or terminate clinical trials where relevant GCP violations affect their completeness or reliability.

3.5 Misconduct involving biological materials

Biotechnology investigations may involve blood, tissues, cells, embryos, genetic material and other biological specimens.

Misconduct may include:

Unauthorized collection of samples.

Use of samples beyond the authorised research purpose.

Improper storage of biological materials.

Unauthorized transfer of biological specimens.

Misuse of human genetic information.

Such activities may engage medical, privacy, research-ethics and other applicable legislation.

4. Institutional mechanisms for investigating research misconduct

Research institutions play an important role in identifying and investigating misconduct.

Typical institutional mechanisms include:

1. Research ethics committees

These committees examine ethical concerns involving human participants, consent, research protocols and participant safety.

2. Scientific integrity committees

They may investigate plagiarism, fabricated results, falsified laboratory records and questionable authorship.

3. Internal audits

Audits can examine laboratory notebooks, experimental records, clinical-trial documentation, research databases and funding expenditure.

4. Institutional disciplinary procedures

Depending on the evidence and employment arrangements, institutions may issue warnings, impose disciplinary measures, terminate employment or refer matters to competent authorities.

5. Regulatory investigations

Where misconduct involves medicines or clinical trials, the competent health regulator may investigate violations and take statutory enforcement action.

6. Funding-related investigations

Where public research funding is involved, financial audits and investigations may examine fraudulent expenditure, false reporting and misuse of allocated research funds.

An important distinction is that an institutional ethics committee's finding does not automatically establish criminal guilt. Criminal liability requires the relevant legal elements to be established through the applicable legal process.

5. Civil, administrative and criminal liability

Research misconduct does not automatically constitute a criminal offence. The applicable legal consequences depend on the conduct, intent, damage and statutory elements.

Legal provisionPotential application
Civil Code Article 1251Protection of intellectual and authorship rights
Civil Code Article 1252Protection of exclusive intellectual property rights
Civil Code Article 1064Compensation for damage
Criminal Code Article 146Copyright infringement and, where statutory requirements are met, plagiarism
Criminal Code Article 159Fraud involving research grants or funding
Criminal Code Article 137Unlawful collection or dissemination of private information
Criminal Code Article 292Official forgery by qualifying public officials
Criminal Code Article 285Abuse of official powers by qualifying officials
Labour Code Article 81Dismissal on applicable statutory grounds
Labour Code Article 192Disciplinary sanctions

These provisions must be applied individually. For example, a scientific error is not automatically fraud, and plagiarism does not automatically satisfy the criminal requirements of Article 146.

6. Important Russian case laws and judicial decisions

Russian courts have addressed research misconduct through disputes concerning academic degrees, plagiarism, clinical research, intellectual property and scientific publications. There is a distinction between cases directly involving biotechnology and cases establishing principles applicable to biotechnology research.

Case 1. Supreme Court of the Russian Federation – Academic degree withdrawal for dissertation plagiarism (2021)

Important judicial precedent

Case background:

The Supreme Court examined a dispute involving a researcher from St Petersburg whose candidate-of-sciences degree had been withdrawn after substantial unattributed borrowing was discovered in her dissertation.

The dispute concerned the interpretation of paragraph 76 of the Government Regulation on Awarding Academic Degrees, approved by Government Resolution No. 842 of 24 September 2013.

The researcher challenged the decision partly because the administrative review had exceeded the prescribed period.

Court's reasoning:

The Supreme Court accepted that the prescribed period was procedural rather than an automatic limitation preventing a decision after its expiry.

It also emphasised that a dissertation must represent independently undertaken scientific work and demonstrate the candidate's personal contribution to science.

Legal principle:

Academic degrees can be withdrawn when serious plagiarism is established.

Procedural delay does not necessarily invalidate an otherwise lawful decision.

Scientific originality and personal contribution are essential requirements of academic research.

Relevance to biotechnology:

This principle applies to biotechnology dissertations involving genetic engineering, pharmaceutical research, molecular biology, genomics and cellular research.

A researcher cannot legitimately obtain an academic degree by presenting another scientist's experimental findings as their own.

Source:

РАПСИ

 

Case 2. Intellectual Property Court – Zhirnov v. Rospatent and Others (2015)

Directly relevant to clinical research evidence

Case number: SIP-864/2014

Decision date: 31 July 2015.

Background:

Oleg Zhirnov brought proceedings concerning statements about clinical research included in Russian Patent No. 2425691.

The patent concerned an aprotinin-based aerosol preparation intended for treating viral respiratory infections.

The claimant disputed the accuracy of the clinical-research information appearing in the patent description.

He argued that the clinical findings relied upon related to a different medicinal preparation and that the information was misleading.

Court's decision:

The Intellectual Property Court rejected the claims.

The court explained that information contained in official documents, where the law provides a separate procedure for challenging those documents, cannot simply be treated as false information subject to ordinary judicial refutation.

The decision was upheld by the Presidium of the Intellectual Property Court on 23 November 2015.

Legal principles:

Scientific claims included in patent documentation may raise issues beyond ordinary copyright disputes.

Official patent and regulatory records must be challenged through the appropriate legal procedures.

Allegations concerning clinical-research falsification require appropriate evidence and legal proceedings.

Patent disputes and scientific misconduct investigations should not be confused.

Relevance to biotechnology:

This case is particularly relevant to pharmaceutical biotechnology, clinical testing, biological medicines, experimental formulations and the reliability of scientific evidence used in patent applications.

Source:

ГАРАНТ

 

Case 3. Moscow City Court – Academic plagiarism and reputation disputes (30 April 2025)

Case number: 33-0743/2025

Background:

The dispute involved allegations of plagiarism in doctoral and candidate dissertations and the publication of accusations concerning academic misconduct.

The litigation included claims concerning allegedly defamatory statements, academic-degree challenges and information published on the Dissernet website.

Legal significance:

The dispute demonstrates that allegations of scientific plagiarism can produce two separate categories of legal proceedings:

Proceedings concerning the validity of an academic degree.

Proceedings concerning the reputation and rights of the person accused of misconduct.

An allegation of plagiarism and a final administrative or academic finding of plagiarism are not necessarily the same thing.

Relevance to biotechnology:

Biotechnology researchers, universities and scientific institutions must ensure that misconduct allegations are supported by documentary evidence, reliable comparisons and appropriate investigative procedures.

Source:

ГАРАНТ

 

Case 4. Russian scientific plagiarism and copyright jurisprudence

Russian copyright jurisprudence recognises that scientific works may receive intellectual property protection.

Under Civil Code Articles 1251 and 1252, authors can seek protection against violations of their intellectual rights.

A researcher's unauthorized reproduction of another scientist's protected work may result in:

Recognition of authorship rights.

Prohibition of unlawful use.

Removal or withdrawal of infringing publications.

Compensation where legally justified.

Other civil remedies.

The distinction between plagiarism as an academic offence and copyright infringement as a legal offence is important. Not every unattributed scientific idea is protected by copyright, because copyright generally protects the expression of ideas rather than ideas, methods or scientific discoveries themselves.

DOI

7. Scientific ethics and research integrity standards

Russian scientific institutions also use institutional research-ethics rules.

For example, the Institute of Sociology of the Federal Center of Theoretical and Applied Sociology of the Russian Academy of Sciences publishes a list of conduct regarded as violations of scientific ethics.

The listed misconduct includes:

Fabrication of data.

Falsification of data.

Misleading scientific statements.

Intellectual property violations.

Damage to the scientific work of other researchers.

These standards provide an institutional framework for evaluating scientific misconduct, although they should not be confused with a comprehensive federal criminal statute.

isras.ru

8. Regulatory authorities and their responsibilities

Authority or institutionMain responsibility
Ministry of Science and Higher EducationScientific policy and academic-degree framework
Ministry of HealthHealthcare and clinical-research regulatory policy
RoszdravnadzorHealthcare supervision and clinical-trial compliance
RospatentPatent and intellectual property administration
RoskomnadzorPersonal-data and information-protection supervision
Research ethics committeesEthical review and participant protection
Scientific institutionsInternal scientific-integrity investigations
Prosecutorial and investigative authoritiesInvestigation of suspected offences within their jurisdiction

The precise authority depends on the type of misconduct.

9. Practical examples of legal application

Example 1: Fabricated genetic research

A university researcher invents DNA sequencing results and publishes them as genuine experimental findings.

Possible consequences include institutional disciplinary proceedings, academic sanctions and civil liability where legally established. Criminal liability requires an independently applicable criminal offence.

Example 2: Falsified vaccine clinical trial

A biotechnology company manipulates vaccine trial records and conceals adverse reactions.

Article 38(12) of Federal Law No. 61-FZ becomes particularly relevant. Regulatory action may include suspension or termination of the trial, alongside other applicable liability.

Example 3: Plagiarised biotechnology dissertation

A researcher copies another scientist's genetic-engineering research without proper attribution.

The academic-degree framework under Government Resolution No. 842, copyright law and employment rules may become relevant.

Example 4: Unauthorized use of genetic information

A biotechnology laboratory discloses identifiable genetic information without a lawful basis.

Federal Law No. 152-FZ and applicable medical confidentiality rules may provide grounds for regulatory and legal action.

Example 5: Misuse of government research funding

A research director submits false invoices and fabricated laboratory expenditure reports to obtain public research funding.

Depending on the evidence and the legal elements, Criminal Code Article 159 concerning fraud may apply.

10. Challenges in regulating biotechnology research misconduct in Russia

Several issues complicate enforcement:

1. Scientific complexity: Determining whether experimental results have been deliberately falsified requires specialist scientific examination.

2. Distinguishing error from misconduct: Incorrect experimental results may arise from genuine methodological mistakes rather than deliberate deception.

3. Institutional conflicts of interest: Universities and research organisations may face conflicts when investigating their own senior researchers or administrators.

4. Genetic-data protection: Genomic research involves highly sensitive information, and unauthorized disclosure may harm research participants and their relatives.

5. International research collaboration: Cross-border biotechnology projects can involve different research-integrity standards, data-protection requirements and contractual obligations.

6. Clinical-trial transparency: Reliable documentation, independent monitoring and accurate adverse-event reporting are necessary to establish the integrity of clinical research.

11. Recommendations for strengthening research misconduct regulation

Russia's biotechnology research-integrity framework could be strengthened through:

Establishing clearer national definitions of fabrication, falsification and plagiarism.

Introducing consistent institutional procedures for investigating scientific misconduct.

Requiring independent investigations where senior researchers are implicated.

Improving laboratory data retention and audit trails.

Strengthening protection for whistleblowers reporting scientific fraud.

Requiring transparent reporting of clinical-trial results and adverse events.

Introducing stronger safeguards for genetic samples and genomic information.

Improving coordination between scientific institutions and regulatory authorities.

Requiring disclosure of conflicts of interest in biotechnology research.

Establishing consistent sanctions proportionate to the seriousness of misconduct.

12. Conclusion

Biotechnology research misconduct regulation in Russia is based on a combination of scientific legislation, healthcare regulation, clinical-trial requirements, personal-data protection, intellectual property law, employment law and criminal legislation.

Federal Law No. 127-FZ provides the general scientific framework, while Federal Law No. 61-FZ specifically addresses Good Clinical Practice violations and falsification of medicinal-product clinical-trial results.

The judicial decisions discussed above demonstrate that Russian courts recognise the importance of scientific originality, reliable clinical evidence, intellectual property protection and procedural fairness.

However, the cases should be understood accurately: the Supreme Court dissertation case concerns academic plagiarism, the Zhirnov case concerns disputed clinical-research information in patent documentation, and the Moscow City Court case concerns academic allegations and reputation. They do not collectively establish a single comprehensive judicial doctrine specifically for biotechnology research misconduct.

The central legal principle is that biotechnology research must be scientifically reliable, ethically conducted, properly documented and compliant with the applicable legal requirements.

13. Important primary legal and research sources

Federal Law No. 127-FZ – On Science and State Scientific and Technical Policy.

Federal Law No. 61-FZ – On Circulation of Medicines.

Federal Law No. 180-FZ – On Biomedical Cellular Products.

Supreme Court decision concerning dissertation plagiarism (2021).

Intellectual Property Court, Case SIP-864/2014.

Moscow City Court, Case 33-0743/2025.

Research study on unauthorized clinical trials in Russia.

Academic note: This is a research-oriented legal overview, not a substitute for checking the latest consolidated Russian legislation and the complete texts of judicial decisions before relying on them in litigation or publication.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT